News

UCB Pharma acquires Engage Therapeutics and with it Staccato Alprazolam a treatment for termination of epileptic seizure.

Read time: 1 mins

Published:9th Jun 2020

UCB announced the acquisition of Engage Therapeutics, Inc. a clinical-stage pharmaceutical company developing Staccato Alprazolam for the rapid termination of an active epileptic seizure, for $ 125 million in cash (subject to certain adjustments) and up to $ 145 million in further potential milestone payments related to clinical development, submission and launch of Staccato Alprazolam.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 mins

Industry news

Antibe Therapeutics has receiver appointed.

Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved

1 min

Industry news

TreeFrog Therapeutics licenses C-Stem technology to Vertex Pharma

Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D)

1 min

See all news